Alkermes reports positive Phase 1b topline for ALKS 7290

Alkermes (NASDAQ:ALKS) said its oral OX2R agonist ALKS 7290 showed dose-dependent clinical improvements and favorable safety in adults with ADHD, with Phase 2 now enrolling. The company also added Anne C. Whitaker to its board through 2027.